Dateline City:
WHITEHOUSE STATION, N.J.
Merck now expects to submit the New Drug Application for odanacatib with the U.S. Food and Drug Administration (FDA) in 2015
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced data from the pivotal Phase 3 fracture outcomes study
for odanacatib in postmenopausal women with osteoporosis. Odanacatib is
Mercks investigational once-weekly cathepsin K inhibitor. In the
Long-Term Odanacatib Fracture Trial (LOFT), odanacatib met its primary
endpoints and significantly reduced the risk of osteoporotic hip, spine
and non-vertebral fractures compared with placebo.
Language:
English
Contact:
MerckMedia:Pam Eisele, 267-305-3558Tracy Ogden, 215-370-5597orInvestors:Justin Holko, 609-915-8293
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more